Vivoryon Therapeutics N.V.

Amsterdam Stock Exchange:VVY.AS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🤖 Artificial Intelligence (AI)

🧬 Biotechnology

💊 Pharmaceuticals

Location

Germany

Market Cap

USD 43.92 M

Share Price

USD 1.68

Avg Daily Volume

53,082

Change (1 day)

-1.02%

Change (1 year)

13.49%

Change (YTD)

-18.24%

Vivoryon Therapeutics N.V. Total Assets for the year ending December 31, 2024

Vivoryon Therapeutics N.V. Total Assets is NA for the year ending December 31, 2024. Total assets are the total value of all assets owned by a company, representing its resources.

Vivoryon Therapeutics N.V. Total Assets for the year ending December 31, 2023 was USD 34.03 M, a 1.36% change year over year.
Vivoryon Therapeutics N.V. Total Assets for the year ending December 31, 2022 was USD 33.57 M, a 20.28% change year over year.
Vivoryon Therapeutics N.V. Total Assets for the year ending December 31, 2021 was USD 27.91 M, a -23.20% change year over year.
Vivoryon Therapeutics N.V. Total Assets for the year ending December 31, 2020 was USD 36.34 M, a -29.39% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Assets	Accounts Payable	Short-Term Debt	Long-Term Debt

Amsterdam Stock Exchange: VVY.AS

Vivoryon Therapeutics N.V.

CEO	Dr. Frank T. Weber M.D.
IPO Date	Oct. 27, 2014
Location	Germany
Headquarters	Weinbergweg 22
Employees	14
Sector	🏥 Health Care
Industries Clinical Trials 🤖 Artificial Intelligence (AI) 🧬 Biotechnology 💊 Pharmaceuticals

Description

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.